AbbVie Updates Exec Team, Creates A Separate Aesthetics Business Unit

The only addition to AbbVie’s leadership after it closes the $63bn acquisition of Allergan will be Carrie Strom, who will lead the Allergan Aesthetics business.

Close up of hands of cosmetologist making botox injection in female face
Allergan's Botox-led aesthetics franchise is a blockbuster business. • Source: Shutterstock

AbbVie Inc. will keep Allergan PLC’s market-leading medical aesthetics business in the hands of Allergan employees who know how to develop and market products in this unique biopharmaceutical and medical device category after the big pharma closes its $63bn acquisition of the specialty firm in the first quarter of 2020.

Allergan senior vice president of US medical aesthetics Carrie Strom will become a senior vice present at AbbVie and president...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Scrip

BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines

 
• By 

Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By 

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.